Navigation Links
Vimpat(R) (lacosamide) C-V, a New Antiepileptic Drug (AED), To Be Available in U.S. Pharmacies
Date:5/26/2009

ll continue to experience seizures despite trying two or more AEDs
  • 200,000 new cases are diagnosed each year, a number that is expected to grow at a faster rate as the population ages

  • Important safety information about Vimpat in the U.S.

    Vimpat tablets are indicated as adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy who are 17 years and older. Vimpat injection is indicated as short-term replacement when oral administration is not feasible in these patients. Patients should be advised that Vimpat may cause dizziness, ataxia, and syncope. Caution is advised for patients with known cardiac conduction problems, who are taking drugs known to induce PR interval prolongation, or with severe cardiac disease. In patients with seizure disorders, Vimpat should be gradually withdrawn to minimize the potential of increased seizure frequency. Multiorgan hypersensitivity reactions have been reported with antiepileptic drugs. If this reaction is suspected, treatment with Vimpat should be discontinued.

    AEDs increase the risk of suicidal behavior and ideation. Patients taking Vimpat should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.

    The most common adverse reactions occurring in greater than or equal to 10 percent of Vimpat-treated patients, and greater than placebo, were dizziness, headache, nausea, and diplopia.

    For more information, and prescribing information visit www.Vimpat.com or contact UCB at (800) 477-7877.

    Vimpat(R) is a registered trademark under license from Harris FRC Corporation.

        For further information
        Andrea Levin, Public Relations Manager, CNS, UCB
        Phone: 770-970-8352
        Em
    '/>"/>
    SOURCE UCB
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related biology technology :

    1. Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting
    2. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
    3. Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD
    4. ValueRich Report on AMDL/China Available on Web Site
    5. AMDL Presentation of China Success Story from Rodman & Renshaw Annual Healthcare Conference Available at WallStreetReporter.com
    6. Arpida-Supported CME Symposium Available Online
    7. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
    8. Free White Paper Available for Clinical Laboratory Managers: Effectively Isolating Anaerobic Bacteria
    9. Neogen Launches Quickest Test Available for Tetracyclines in Milk
    10. Vaccinogens New Anti-Cancer Vaccine Commercially Available in Europe This Year
    11. Canadas Best-Selling Soymilk Now Available with Marteks lifesDHA
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/22/2014)... CHAPEL HILL, N.C. , Dec. 22, 2014 ... ALNE) today announced that it has signed a ... biotechnology company that has developed and patented a ... and medical diagnostics products that enable rapid on-site ... and alcohol use/abuse and health issues in an ...
    (Date:12/22/2014)... The American Journal of Hematology/Oncology, a ... editorials addressing developments and pathways related to oncological ... article exploring the role of follicle-stimulating hormone (FSH) ... prostate cancer. , The article references seminal ... there could be a connection to prostate cancer ...
    (Date:12/19/2014)... Hershey, PA (PRWEB) December 19, 2014 ... a leading developer and manufacturer of needle-free injection ... an agreement with Immunomic Therapeutics, Inc. (“ITI”) for ... injection device with its LAMP™ vaccine platform. ... for an exclusive Worldwide license to the Biojector®-2000 ...
    (Date:12/19/2014)... 2014 Naurex Inc., a biopharmaceutical company leveraging ... of the central nervous system, today announced that ... will present at the 33 rd annual J.P. ... at 3:00 p.m. PST on Tuesday, January 13, 2015, ... Francisco, Calif. About Naurex ...
    Breaking Biology Technology:ALNE Announces Intention To Acquire BioTechPharma 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
    ... China, May 11 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical,Inc. ... CSKI ), a leading,fully integrated pharmaceutical company producing ... announced that it will conduct a,conference call at 10:00 ... to discuss its first quarter of fiscal year 2009 ...
    ... DIEGO, May 11, 2009 Arena Pharmaceuticals, Inc. (Nasdaq: ... quarter ended March 31, 2009. Arena reported a net loss ... of $50.6 million, or $0.68 per share, compared to a ... of 2008 of $55.0 million, or $0.75 per share. "Receiving ...
    ... Inc. (OTC Bulletin Board: SNBP) ("Sinobiopharma" or, the ... received approval from the Chinese State Food and ... formulation of Perindopril, an anti-hypertension drug.Perindopril, used alone ... high blood pressure, is the latest generation of ...
    Cached Biology Technology:China Sky One Medical, Inc. Schedules Conference Call to Discuss First Quarter 2009 Results 2China Sky One Medical, Inc. Schedules Conference Call to Discuss First Quarter 2009 Results 3Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 2Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 3Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 4Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 5Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 6Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 7Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 8Sinobiopharma Announces SFDA Approval of Anti-Hypertension Drug Perindopril 2
    (Date:12/10/2014)... Dec. 9, 2014 CIE San Diego has ... provides the connective tissue that enhances care coordination among ... easily share client-level information; earned a second $1 million ... organizations serving seniors aging in community and; will be ... December 11 th 4-6p. CIE San ...
    (Date:12/4/2014)... Fla. , Dec. 3, 2014  Crossmatch™, ... today announced that its DigitalPersona ® Pro ... readers have been deployed throughout First Bank branch ... South Carolina and Virginia. First ... Southern Pines, North Carolina , ...
    (Date:11/21/2014)... 20, 2014 Strict laws against distracted driving ... the North American and European automotive sector towards gesture ... recognition systems that are intuitive and able to retrieve ... industry. New analysis from Frost & ... in Europe and ...
    Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
    ... Bonn Institute for Forensic Medicine has recorded that the ... sexual offences within their catchment area increased 10-fold between ... Deutsches rzteblatt International, Burkhard Madea and Frank Musshoff ... for the most frequent substances ( Dtsch Arztebl Int ...
    ... should be built in Lund, Sweden, it has been announced ... last night (28 May), seven countries voted in support of ... a further two voting with the majority. The European ... for materials research, enabling scientists to study the atomic and ...
    ... of a USC-led research team say they,ve made a big ... and other biological materials one that may be a ... of a piece of synthetic antibody attached to a nanowire ... If the protein the antibody binds to is present in ...
    Cached Biology News:Sweden to host 1.3 billion Euro research center 2A quicker, cheaper SARS virus detector -- one easily customizable for other targets 2
    ... RNAi Kit is optimized for ... amounts of ready-to-use dsRNA for ... The MEGAscript RNAi Kit is ... transcription technol-ogy and includes reagents ...
    ... actuators as building blocks, Parker can ... ,robotic solutions that are ideal for ... base ,system, Parker can also integrate ... structures, and ,guarding., Standard or ...
    ... is the smallest electronic pressure controller ... mm. Parker configured this unit specifically for ... markets. Used in carrier gas flow control, ... dispensing, and hydro-dynamic focusing, the OEM-EPC offers ...
    ...
    Biology Products: